GlassScriptPhysician profile
Lawrence W Johnson
NPI 1619968641
$3,276.95
in general payments reported to CMS, 2019-2025
19 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $160 · 2021: $505 · 2022: $465 · 2023: $563 · 2024: $522 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $496.01 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $443.31 | 2019-2025 | Entyvio, Gattex |
| Genzyme Corporation | $366.49 | 2022-2025 | |
| Janssen Biotech, INC. | $305.50 | 2019-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $150.00 | 2025 | General - Hemostasis |
| Pfizer INC. | $148.50 | 2019-2025 | |
| Qol Medical, LLC | $104.35 | 2023-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $52.70 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $38.80 | 2020-2023 | Dificid |
| Lilly USA, LLC | $32.31 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $29.97 | 2019-2022 | |
| Allergan, INC. | $25.21 | 2019 | |
| Aimmune Therapeutics, INC. | $22.87 | 2024 | |
| Celgene Corporation | $22.47 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.34 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.06 | 2023 | Cyltezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.02 | 2019 | |
| Evoke Pharma, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.